Type 2 diabetes patients undergoing treatment with a drug belonging to the incretin mimetic class, such as Onglyza, Victoza, or Saxenda, may be at risk for a wide range of serious or possibly even life-threatening medical conditions, such as heart failure, pancreatitis, and pancreatic cancer. While some people with type 2 diabetes have found the successful treatment of their disease ...
